Background: The ERAP1 gene cleaves the receptors and reduces their ability to transmit chemical signals to the cell that affect the process of inflammation and, secondly, it cleaves many types of proteins into small peptides that are recognized by the immune system.
Introduction
The endoplasmic reticulum aminopeptidase-1 (ERAP-1) gene provides instructions for making a protein called endoplasmic reticulum aminopeptidase. First, it involves aminopeptidase, which is an enzyme that cleaves other proteins into peptides. Endoplasmic reticulum aminopeptidase cleaves the receptors and reduces their ability to transmit chemical signals to the cells, and thus affects the process of inflammation. Secondly, it cleaves many types of proteins into small peptides that are recognized by the immune system. These peptides are exported to the cell surface where they attach to major histocompatibility complex (MHC) class I proteins. MHC class I proteins display these peptides to the immune system. If the immune system recognizes the peptides as foreign (such as viral or bacterial peptides), it responds by triggering the self-destruction of the infected cell.
Turkish, North African Jewish, Arabic and Armenian populations. It is characterized by episodic attacks of inflammation in the peritoneum, synovium or pleura accompanied by fever and skin rash. However, it is usually hard to diagnose FMF because of very heterogeneous symptoms and subjective laboratory findings. The discovery of the pyrin gene mutations in patients with FMF caused huge expectations for the accurate diagnosis of the disease. However. pyrin gene mutations are not always helpful for the diagnosis of the disease. [7] [8] [9] [10] [11] [12] [13] [14] [15] FMF has three basic genetic forms: 1) genetically and phenotypic-positive patients, 2) genetically negative but phenotypic-positive patients, and 3) genetically positive but phenotypic-negative patients. Owing to the heterogeneity of the presentation, we still need some other markers to diagnose the disease. ERAP-1 is essential for the maturation of a wide spectrum of proteins involved in various biological processes. Loss of ERAP-1 function substantially alters the repertoire of peptides presented by MHC class I molecules, critically affecting recognition of both natural killer and CD8þ T cells. In addition these enzymes are involved in the modulation of inflammatory responses by promoting the shedding of several cytokine receptors and the regulation of both blood pressure and angiogenesis. 1 Ulcerative colitis (UC) is an idiopathic, chronic inflammatory bowel disease that may present with arthritis. Non-MHC susceptibility loci such as ERAP-1 are likely contributors to the inflammation in UC. In fact, if compared to other complex diseases such as ankylosing spondylitis (AS), fewer susceptibility loci have been identified in UC. 16 All of the physiopathogenetic mechanisms related to the ERAP-1 gene mutations have been studied, especially in patients with UC. [1] [2] [3] [4] [5] [6] UC is an auto-inflammatory disease like FMF. The association with the ERAP-1 mutations has been shown to be very strong in this disease; therefore, we selected UC patients as a control group.
We hypothesized that ERAP-1 gene mutations may promote pyrin gene mutations or exist together with pyrin gene mutations in FMF patients. We included only FMF patients with the M694 (þ) mutation to exclude patients without pyrin gene mutations and create a homogeneous study group. We compared FMF patients with the patients with UC, which is a disease previously shown to have a relation with ERAP-1 gene mutations.
Material and methods
This is a case-control study of ERAP-1 gene mutations in serum from patients with FMF (study group) and from patients with UC (control group). Fifteen patients with FMF fulfilling Tel-Hashomer criteria and also known to be positive for the M694 pyrin mutation (heterozygote or homozygote) and 15 
Detection of serum ERAP-1 gene mutations
Peripheral blood (10 ml) samples were obtained from each patient and centrifuged at 3500 rpm to obtain serum. Serum was deposited in an Eppendorf tube at -70 C for subsequent processing until assayed for ERAP-1. Analysis of ERAP-1 gene mutations at exon 3 and exon 10 in both the study group and the control group were performed with polymerase chain reaction (PCR)-DNA folders. Primer pairs were used at 0.6 pico mole/ml. The other PCR components were 10 mM TrisHCl (25 C pH: 8.8), 50 mM KCl, 0.2 mM deoxynucleotide 3 0 -phosphate (dATG, dGTP, dCTP, dTTP (Fermentas, Lithuania)) and 15 mM MgCl 2 .
ERAP-1 gene primers at exon 3
ERAP-1 gene primers at exon 10
0 . After denaturation and hybridization (Applied Biosystems, USA) of PCR products, amplification of the right gene region was checked by agarose gel.
After purification of the samples (Bio Basic, Canada), new PCR cycling was performed and purified again. At the end of this process samples were loaded into the DNA folders analyzer (Applied Biosystems 3130xl, USA). Obtained results were analyzed by SeqScape Õ Software, v 3.0.
Statistical analysis
Because of the small number of both groups, we didn't perform any statistical evaluation between the two groups.
Results
There wasn't any case without ERAP-1 gene mutations. At least one mutation at exon 3 or exon 10 was found in all cases in both groups.
There were 14 ERAP-1 gene mutations at exon 10 and 11 ERAP-1 gene mutations at exon 3 in patients with FMF. Exon 3 mutations were usually a single p.Arg127 Pro (c.380 G>C) mutation for eight patients with FMF. Interestingly, if there were ERAP-1 gene (Tables 1 and 2 ). There were 11 ERAP-1 gene mutations at exon 10 and 12 ERAP-1 gene mutations at exon 3 in patients with UC. Exon 3 mutations were usually single p.Arg127 Pro (c.380 G>C) mutations for 12 patients with UC, similar to patients with FMF. There were polymorphic ERAP-1 gene mutations in three patients: p.Arg127 Pro (c.380 G>C) þ p.Thr12Ile Pro (c.35 C>T) þ a p. Tyr57Tyr (c.171 C>T) mutation in one patient; p.Arg127 Pro (c.380 G>C) þ p.Thr12Ile Pro (c.35 C>T) in one patient; and p.Arg127 Pro (c.380 G>C) þ p.Glu56Lys (c.166 G>C) in one patient. There were 11 single ERAP-1 gene mutations at exon 10 in UC patients. There were no mutations at exon 10 in four patients with UC. The single mutation was always p.Ser453 Ser (c.1359T>C) for patients with UC at exon 10 (Tables 1 and 2 ).
Discussion
We could not make any statistical evaluation between the FMF group and UC patients owing to the small number of patients but we determined that there are more ERAP-1 mutations in the FMF group than in the UC group. So, there may be a strong susceptibility to ERAP-1 gene mutations in FMF patients according to our results. All patients with FMF in this study had the M694 mutation, which is the most common mutation in Turkish patients with FMF. So, our FMF population was quite homogeneous. This homogeneity may also lead us to suspect an association of the ERAP-1 gene mutation with the M694 mutation as well.
However, there are some limitations of this study. The most important one is the numbers in our study groups. Both study and control groups are very small because of financial difficulties. Second, we did not look at the ERAP-1 mutations in a normal population. We tried to overcome these difficulties first by setting up a homogeneous FMF study group and second by making a comparison with UC, which is considered as having a similar etiopathogenesis.
FMF is a very heterogeneous disease and it has been shown before that in FMF there are pyrin gene mutations. Some other mutations can also exist. The ERAP-1 gene controls a very important enzyme that helps to recognize proteins. Single nucleotide polymorphisms within the aminopeptidase ERAP-1 are essential for trimming peptides before they are presented to T cells. ERAP-1 is a highly polymorphic molecule comprising allotypes of single nucleotide polymorphisms. Therefore there is strong evidence that polymorphic ERAP-1 alters protein function, predisposing an individual to disease via its influence on the antigen-processing pathway. This step is very important for the initiation of inflammation. On the other hand, pyrin controls the end of inflammation. Pyrin is produced in certain white blood cells that play a role in inflammation. But pyrin assists in keeping The discovery of ERAP mutations in patients with FMF should not be a surprise. But, this is the first ERAP-1 study in FMF patients. This is a pilot study with a very robust positive result. However, further studies with larger study and control groups are needed. We believe that the evaluation of ERAP mutations in FMF patients will help us to find new tools for the correct diagnosis of the disease. This study may provide a step forward in finding a new susceptibility gene in FMF.
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